Development of novel digital biomarkers for proactive detection and treatment of functional decline
开发新型数字生物标志物,用于主动检测和治疗功能衰退
基本信息
- 批准号:10484214
- 负责人:
- 金额:$ 29.98万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-06-15 至 2024-05-31
- 项目状态:已结题
- 来源:
- 关键词:Activities of Daily LivingAddressAdoptionAdultAgeAlzheimer&aposs DiseaseAlzheimer&aposs disease related dementiaAmericanAmerican Medical AssociationAreaBehavior TherapyBiological MarkersCaringChicagoClinicClinicalCommunitiesComputer Vision SystemsConsultationsDataDementiaDetectionDevelopmentDevicesDiagnosisEarly DiagnosisElderlyExerciseExpenditureFatigueFutureGeriatricsGoldHealthHealth Care CostsHomeIllinoisImpaired cognitionJointsLaboratoriesLifeLinkLocationMarket ResearchMeasuresMedicalMedicineMethodsModelingMonitorMovementOutcomeOwnershipPainPeriodicityPersonsPhasePreventionQuality of lifeRiskSelf AdministrationSeveritiesSiteSmall Business Innovation Research GrantSocializationStep TestsTechnologyTensorFlowTestingTimeTrainingUniversitiesadverse outcomeagedaging populationbasecommercializationcostcost effectivedigitaldigital computingdisabilityeconomic impactevidence baseexercise prescriptionexercise trainingexperiencefitnessfunctional declinehandheld mobile devicehealth economicsimprovedinnovationmachine learning modelmobile applicationnew technologynovelpandemic diseasepreventpreventive interventionprototypescreeningsoftware developmenttechnology developmenttreatment response
项目摘要
PROJECT SUMMARY
By age sixty-five, 1 in 4 Americans will experience functional decline, a “silent killer” defined by life altering loss
of independence and limitations performing activities of daily living (ADLs). Poor health outcomes and
skyrocketing costs linked to functional decline cut across many diagnoses, leading to national expenditures
projected to exceed $1 trillion annually. Routine functional screening assessments are the gold-standard for
addressing this condition. However, due to numerous barriers, most older adults are cared for in settings
where screening is poor, inaccurate, or not conducted at all. As a result, functional decline often goes
unnoticed until obvious disability and adverse outcomes occur. Leaders in geriatrics have long recognized
obstacles addressing functional decline and have called for improved screening and treatment approaches.
Meanwhile, ownership, adoption, and usage of digital devices has climbed sharply among older adults,
particularly during the pandemic. Smyl Fitness Rx, LLC (Smyl) has identified a novel method to use these
devices to address functional decline. This Phase I SBIR proposes development of a mobile application
powered by technology that will offer a scalable solution to automate functional screening assessments,
compute novel digital biomarkers of functional decline, and deliver evidence-based fitness prescriptions with
behavior modification features to facilitate ongoing treatment and prevention. Smyl developed a framework for
the application in consultation with key opinion leaders from the American Medical Association’s (AMA’s)
Exercise Is Medicine (EIM) advisory board been and tested it with older adults. Commercialization will focus on
addressing key pain points and unmet needs identified during Smyl’s market research. Aim 1 will focus on
developing machine learning models that use computer vision technology to automate routine functional
assessments. Computer vision technology has shown to be effective for use among older adults, including
those with dementia. Aim 2 will consist of developing analytic models that use parameters from the automated
assessment to compute novel digital biomarkers of functional decline. These digital biomarkers will indicate the
presence or future risk of functional decline, ongoing severity, and response to treatment. In Aim 3 Smyl will
develop a movement quality & fitness prescription model to facilitate safe and effective exercise prescriptions
shown to address functional decline. Phase II efforts will focus on optimizing the technology for home use,
developing data-driven fitness prescriptions, and enhancing the platform for use among people living with
Alzheimer's disease and Alzheimer's disease-related Dementias (AD/ADRD). The scientific and technology
developments of this project have the potential to impact over 34 million middle and older age adults.
Implementation of the proposed innovation could reduce the loss of independence, poor health outcomes, and
skyrocketing health costs associated with functional decline.
PROJECT SUMMARY
By age sixty-five, 1 in 4 Americans will experience functional decline, a “silent killer” defined by life altering loss
of independence and limitations performing activities of daily living (ADLs). Poor health outcomes and
skyrocketing costs linked to functional decline cut across many diagnoses, leading to national expenditures
projected to exceed $1 trillion annually. Routine functional screening assessments are the gold-standard for
addressing this condition. However, due to numerous barriers, most older adults are cared for in settings
where screening is poor, inaccurate, or not conducted at all. As a result, functional decline often goes
unnoticed until obvious disability and adverse outcomes occur. Leaders in geriatrics have long recognized
obstacles addressing functional decline and have called for improved screening and treatment approaches.
Meanwhile, ownership, adoption, and usage of digital devices has climbed sharply among older adults,
particularly during the pandemic. Smyl Fitness Rx, LLC (Smyl) has identified a novel method to use these
devices to address functional decline. This Phase I SBIR proposes development of a mobile application
powered by technology that will offer a scalable solution to automate functional screening assessments,
compute novel digital biomarkers of functional decline, and deliver evidence-based fitness prescriptions with
behavior modification features to facilitate ongoing treatment and prevention. Smyl developed a framework for
the application in consultation with key opinion leaders from the American Medical Association’s (AMA’s)
Exercise Is Medicine (EIM) advisory board been and tested it with older adults. Commercialization will focus on
addressing key pain points and unmet needs identified during Smyl’s market research. Aim 1 will focus on
developing machine learning models that use computer vision technology to automate routine functional
assessments. Computer vision technology has shown to be effective for use among older adults, including
those with dementia. Aim 2 will consist of developing analytic models that use parameters from the automated
assessment to compute novel digital biomarkers of functional decline. These digital biomarkers will indicate the
presence or future risk of functional decline, ongoing severity, and response to treatment. In Aim 3 Smyl will
develop a movement quality & fitness prescription model to facilitate safe and effective exercise prescriptions
shown to address functional decline. Phase II efforts will focus on optimizing the technology for home use,
developing data-driven fitness prescriptions, and enhancing the platform for use among people living with
Alzheimer's disease and Alzheimer's disease-related Dementias (AD/ADRD). The scientific and technology
developments of this project have the potential to impact over 34 million middle and older age adults.
Implementation of the proposed innovation could reduce the loss of independence, poor health outcomes, and
skyrocketing health costs associated with functional decline.
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Terrance Walless其他文献
Terrance Walless的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 29.98万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 29.98万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 29.98万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 29.98万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 29.98万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 29.98万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 29.98万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 29.98万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 29.98万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 29.98万 - 项目类别:
Research Grant